These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19461177)

  • 1. [Serum HER-2 determination using a centauer HER-2/neu kit (CLIA method) in metastatic breast cancer].
    Kan N; Yoshikawa S
    Gan To Kagaku Ryoho; 2009 May; 36(5):779-83. PubMed ID: 19461177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the measurement of serum extracellular domain of HER-2/neu protein with CLIA method.
    Kuroda N; Kontani K; Kajikawa T; Taminato T
    Rinsho Byori; 2010 Jun; 58(6):541-52. PubMed ID: 20662264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
    Schippinger W; Regitnig P; Bauernhofer T; Ploner F; Hofmann G; Krippl P; Wehrschütz M; Lax S; Carney W; Neumann R; Wernecke KD; Samonigg H
    Oncol Rep; 2004 Jun; 11(6):1331-6. PubMed ID: 15138574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
    Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
    Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer.
    Kuerer HM; Thompson PA; Krishnamurthy S; Fritsche HA; Marcy SM; Babiera GV; Singletary SE; Cristofanilli M; Sneige N; Hunt KK
    Clin Cancer Res; 2003 Feb; 9(2):601-5. PubMed ID: 12576424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum her-2/neu level and related factors in patients with breast cancer].
    Yuan P; Xu BH; Zhang C; Qi J
    Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):573-4. PubMed ID: 14690565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
    Ali SM; Carney WP; Esteva FJ; Fornier M; Harris L; Köstler WJ; Lotz JP; Luftner D; Pichon MF; Lipton A;
    Cancer; 2008 Sep; 113(6):1294-301. PubMed ID: 18661530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum HER-2 concentration in patients with primary breast cancer.
    Kong SY; Kang JH; Kwon Y; Kang HS; Chung KW; Kang SH; Lee DH; Ro J; Lee ES
    J Clin Pathol; 2006 Apr; 59(4):373-6. PubMed ID: 16461567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial serum c-erbB-2 levels in patients with breast carcinoma.
    Volas GH; Leitzel K; Teramoto Y; Grossberg H; Demers L; Lipton A
    Cancer; 1996 Jul; 78(2):267-72. PubMed ID: 8674002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
    Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.
    Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G
    Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer.
    Lüftner D; Mazurek S; Henschke P; Mesterharm J; Schildhauer S; Geppert R; Wernecke KD; Possinger K
    Anticancer Res; 2003; 23(2A):991-7. PubMed ID: 12820337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
    Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative clinical evaluation of the assay of serum extracellular domain of HER2 protein using a chemiluminescent immunoassay method in breast cancer patients with or without HER2 protein expression in immunohistochemistry.
    Mokuyasu S; Suzuki Y; Seto T; Miyachi H; Tokuda Y
    Rinsho Byori; 2012 Jul; 60(7):612-20. PubMed ID: 22973719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
    Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
    J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An investigation of extracellular HER-2/NEU domain level in blood serum from breast cancer patients].
    Korytova LI; Masliukova EA; Ovchinnikov IV; Filipenko MO; Korytov OV; Kudaĭbergenova AG
    Vopr Onkol; 2010; 56(1):62-5. PubMed ID: 20361618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum big endothelin-1 levels in female patients with breast cancer.
    Yildirim Y; Gunel N; Coskun U; Sancak B; Bukan N; Aslan S; Cetin A
    Int Immunopharmacol; 2008 Aug; 8(8):1119-23. PubMed ID: 18550016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer.
    Garoufali A; Kyriakou F; Kountourakis P; Yioti I; Malliou S; Nikaki A; Kardara E; Frangos I; Koumna S; Baziotis N; Scorilas A; Ardavanis A
    J BUON; 2008; 13(3):409-13. PubMed ID: 18979558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentration of serum HER-2/neu as a prognostic factor in locally advanced breast cancer (LABC) and metastatic breast cancer (MBC).
    Purwanto I; Kurnianda J; Hariadi KW; Harijadi ; Aryandono T; Setiaji K; Harianti MS; Haryana SM
    Acta Med Indones; 2011 Jan; 43(1):23-8. PubMed ID: 21339542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2/neu analysis in breast cancer bone metastases.
    Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
    J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.